THLD
Threshold Pharmaceuticals, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Nov. 15, 2012, 8:49 AM

    Updated results from a Phase II trial of Threshold's (THLD) TH-302 treatment suggest that the drug can be used in patients with soft-tissue sarcoma, first in combination with chemotherapy doxorubicin, and then on its own as a maintenance treatment. The results support Phase III trials of the regimen. Threshold shares +10.3%. (PR)

    | Nov. 15, 2012, 8:49 AM